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A B S T R A C T
Background: Epilepsy aﬀects around 1% of people, but existing antiepileptic drugs (AEDs) only oﬀer sympto-
matic relief and are ineﬀective in approximately 30% of patients. Hence, new AEDs are sorely needed. However,
a major bottleneck is the low-throughput nature of early-stage AED screens in conventional rodent models. This
process could potentially be expedited by using simpler invertebrate systems, such as the nematode
Caenorhabditis elegans.
New method: Head-bobbing convulsions were previously reported to be inducible by pentylenetetrazol (PTZ) in
C. elegans with loss-of-function mutations in unc-49, which encodes a GABAA receptor. Given that epilepsy-linked
mutations in human GABAA receptors are well documented, this could represent a clinically-relevant system for
early-stage AED screens. However, the original agar plate-based assay is unsuited to large-scale screening and
has not been validated for identifying AEDs. Therefore, we established an alternative streamlined, higher-
throughput approach whereby mutants were treated with PTZ and AEDs via liquid-based incubation.
Results: Convulsions induced within minutes of PTZ exposure in unc-49 mutants were strongly inhibited by the
established AED ethosuximide. This protective activity was independent of ethosuximide’s suggested target, the
T-type calcium channel, as a null mutation in the worm cca-1 ortholog did not aﬀect ethosuximide’s antic-
onvulsant action.
Comparison with existing method: Our streamlined assay is AED-validated, feasible for higher throughput com-
pound screens, and can facilitate insights into AED mechanisms of action.
Conclusions: Based on an epilepsy-associated genetic background, this C. elegans unc-49 model of seizure-like
activity presents an ethical, higher throughput alternative to conventional rodent seizure models for initial AED
screens.
1. Introduction
Epilepsy is a brain disorder that results in the development of
neuronal networks predisposed to the occurrence and recurrence of
symptomatic epileptic seizures (Duncan et al., 2006). Epilepsy is one of
the most prevalent neurological conditions, with an estimated 50 mil-
lion suﬀerers worldwide (WHO, 2018). Although there are currently
over 20 approved anti-epileptic drugs (AEDs), these medications pro-
vide only seizure relief and are neither disease-modifying nor able to
prevent epileptogenesis, the pathobiological process which engenders
the development of epilepsy (Brodie et al., 2011; Santulli et al., 2016;
Schmidt and Schachter, 2014). Furthermore, although 70% of patients
respond to AED treatment, the remaining 30% are refractory to cur-
rently available AEDs (Remy and Beck, 2006). Therefore, there is an
unmet need for new AEDs that can impact on pharmacoresistant epi-
lepsy and epileptogenesis.
Current AEDs on the market were either discovered through
screening in rodent seizure models, or developed as derivatives of pre-
existing drugs (Bialer, 2012). Acute seizure induction in mouse and rat
models has conventionally been performed either by the subcutaneous
administration of the convulsant agent pentylenetetrazol (PTZ) or by
trans-corneal electrical stimulation (maximal electroshock, MES)
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(Löscher, 2011). These procedures have been in use for over 60 years,
and despite not recapitulating the complex aetiology of epilepsy, are
still used as primary screening platforms to initially assess activity prior
to further evaluation in more sophisticated models (Löscher, 2011).
However, ethical issues and the ﬁnancial costs associated with the use
of such higher organisms makes them unsuitable for high-throughput
early-stage drug screens, especially when large compound libraries such
as those employed in modern pharmaceutical development are to be
assessed.
These limitations have led to the increasing use of non-mammalian
seizure models in recent years (Baraban, 2007; Cunliﬀe et al., 2015).
The fruit ﬂy, Drosophila melanogaster, and the zebraﬁsh, Danio rerio,
have been at the forefront of this area, providing new genetic models of
epilepsy and the capacity to perform high-throughput drug screens
(Baines et al., 2017; Copmans et al., 2017). In contrast, although the
nematode Caenorhabditis elegans has been extensively used to model a
wide variety of neurological disorders (Chen et al., 2015a), there are
relatively few studies where it has been used as a model organism for
the study of epilepsy (Jospin et al., 2009; Pandey et al., 2010; Risley
et al., 2016; Williams et al., 2004). However, early observations of PTZ-
inducible seizure-like phenotypes (Locke et al., 2009; Williams et al.,
2004) suggest the possibility of developing C. elegans platforms to re-
place conventional PTZ-induced rodent seizure models for early-stage
AED discovery. This presents an attractive alternative, as the use of C.
elegans oﬀers various important advantages. Speciﬁcally, it is pre-
dominantly hermaphroditic, has a short generation time (3 days) and
lifespan (3 weeks), and is highly tractable genetically. This means that
genetic models of epilepsy can be generated much more easily and on a
shorter timescale than is achievable with rodent systems (Baraban,
2007; Cunliﬀe et al., 2015; Takayanagi-Kiya and Jin, 2017). In addi-
tion, its facile molecular genetics enables insights into epileptogenic
processes and AED mechanisms of action, contributing towards the
development of improved AEDs. Lastly, the use of nematode worms is
associated with very low costs and the absence of ethical regulations,
both of which are factors that limit the utility of rodents.
In view of the attractive prospects of employing C. elegans as an
alternative platform to overcome the limitations associated with con-
ventional rodent models in AED development, our work seeks to expand
on past observations of PTZ-induced seizure-like activity in C. elegans,
to develop a streamlined nematode worm model suitable for primary
AED screening.
2. Materials and methods
2.1. Materials
All chemicals were obtained from Sigma (Poole, UK), except for
DNA polymerase and restriction enzymes, which were from New
England Biolabs (Hitchin, UK).
2.2. Nematode strains and maintenance
The following C. elegans strains were obtained from the
Caenorhabditis genetics centre (CGC; University of Minnesota, USA):
Wild type (WT) Bristol N2, unc-43 (n498n1186) IV, cca-1 (ad1650) X,
unc-25 (e156) III, and unc-49 (e407) III. The unc-49 (e407) and unc-25
(e156) alleles are single point mutations that introduce premature stop
codons and have been shown to be genetic nulls (Bamber et al., 1999;
Jin et al., 1999). The unc-43 (n498n1186) allele combines both missense
and nonsense mutations and is presumed to be a genetic null (Reiner
et al., 1999). The cca-1 (ad1650) allele contains a 2.5 kb deletion within
the coding region that removes multiple exons and introduces a fra-
meshift and has been shown to be a null mutant (Steger et al., 2005).
The double mutant unc-49;cca-1 strain was generated from genetic
crosses of unc-49 (e407) III and cca-1 (ad1650) X strains (described
below). Worms were grown and maintained on OP50 E. coli-seeded
nematode growth medium (NGM; 1mM each of CaCl2 and MgSO4,
25mM KH2PO4, 5 μg/mL cholesterol, and in w/v 2% agar, 0.25%
peptone, and 0.3% NaCl) agar in 60-cm plastic petri dishes at 20 °C
(Brenner, 1974). All subsequent procedures as described below were
performed at 20 °C.
2.3. Generation of unc-49;cca-1 double mutants
C. elegans males carry a single copy of the X chromosome, hence
male cca-1 (ad1650) X-linked mutants were derived by mating wild
type (WT) Bristol N2 males with self-fertilising homozygous cca-1
(ad1650) mutant hermaphrodites. The resultant cca-1 (ad1650) males
were crossed with unc-49 (e407) hermaphrodites to derive unc-49;cca-1
double mutants, selected based on various phenotypic characteristics of
the unc-49 mutation: PTZ sensitivity, reduced thrashes in liquid relative
to cca-1 (ad1650) mutants, and a “shrinker” phenotype of body con-
traction and shortening in response to anterior and posterior touch
stimuli (McIntire et al., 1993). Homozygous inheritance of the cca-1
(ad1650) mutation was veriﬁed with PCR primers [forward: 5′−CCG
CAATTTGCCCTCCACAT-3′; reverse: 5′- ATGAGGATGGCGAAGAGG
ACC-3′] which generate diﬀerentially-sized products for WT (3310 bp)
and mutant (930 bp) alleles. Genotyping of unc-49 (e407) homo-
zygosity was performed by initial ampliﬁcation of the point mutation-
harbouring exon with PCR primers [forward: 5′- ATGACCAAGGTTAG
GCGACG-3′; reverse: 5′- TCTGGCTACATAACGGCACG-3′], followed by
subsequent restriction digestion of products with MseI, which distin-
guishes between WT and mutant unc-49 alleles based on the number of
T^TAA cleavage sites and the size of digested fragments (WT: 259 and
172 bp; mutant: 258, 120, 53 bp).
2.4. Age synchronization
Cultured populations on NGM plates wereage-synchronized by
bleaching (2 parts 8% commercial alkaline hypochlorite bleach and 1
part 5M NaOH). Eggs were released from gravid adult worms through
lysis by vortexing the mixture every 2min. for 10min., followed by
pelleting via centrifugation (1min, 1300 g) and subsequent depositing
of egg pellet onto seeded NGM plates. The developmental duration from
egg to adulthood age day 1 of approximately 3.5 days at 20 °C was
adjusted accordingly to attain synchronized populations of older adult
worms of deﬁned ages.
2.5. Plate-based assay
The induction of head-bobbing convulsions by a plate-based ad-
ministration of PTZ was adapted from a previously described protocol
(Williams et al., 2004). The pre-existing method described the pre-
paration of PTZ-containing NGM agar plates through the direct addition
of PTZ to the molten NGM medium to obtain the required working
concentrations, which were subsequently seeded with OP50. Mod-
iﬁcations herein involved preparation of these plates via spreading of a
50X PTZ stock of the required exposure concentration on the surface of
solidiﬁed agar plates prior to seeding. For this purpose, PTZ stock so-
lutions were prepared in water at a 50-fold higher concentration than
the desired ﬁnal concentration. Then a volume of this 50X stock equal
to 1/50 of the NGM plate volume was added to achieve the desired ﬁnal
1X concentration. For example, for a 10ml NGM agar plate one would
spread 200 μL of 50mg/mL PTZ stock to get a 1mg/mL ﬁnal PTZ
concentration. Unsynchronized young gravid adult nematodes dis-
playing no obvious morphological deterioration were selected visually
and transferred to OP50-seeded plates and observed for seizure-like
activity for 30min.
2.6. Liquid-based assay
Liquid-based administration of PTZ was performed by incubating
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individual young (1–3 days old) adult nematodes in 50 μl liquid dro-
plets of PTZ dissolved in Dent’s Ringer solution (DRS; 140mM NaCl,
1 mM MgCl2, 3 mM CaCl2, 6 mM KCl, 10mM HEPES, pH 7.4) con-
taining 0.1% bovine serum albumin (BSA). Droplets were applied to
empty plastic petri dishes, with 0.1% BSA included to prevent worms
sticking to the plastic. Assays to determine optimal PTZ exposure con-
ditions for convulsion induction utilised PTZ concentrations up to
10mg/ml for treatment durations up to 60min. Unless speciﬁed
otherwise, nematodes were exposed to 7mg/ml PTZ for 15min.
2.7. Pharmacological treatment
Treatment of nematodes was initiated prior to and continued
throughout the duration of PTZ administration to ensure uninterrupted
exposure to the pharmacological agent. The validity of the various PTZ-
responsive convulsion-prone strains was assayed with the reference
AED ethosuximide, which displays anticonvulsive activity in conven-
tional PTZ-induced rat and mouse seizure models (Löscher, 2011). In-
itial veriﬁcation of ethosuximide’s anticonvulsive activity was carried
out using a previously established longevity-enhancing concentration of
2mg/ml (Chen et al., 2015b; Evason et al., 2005), following which
further optimisation of treatment conditions was performed with up to
4mg/ml of the drug for treatment durations up to 4 h.
Plate-based administration of ethosuximide was performed by cul-
turing young adult nematodes for 2 days on ethosuximide-containing
NGM agar plates prepared by directly diluting a stock solution of the
drug dissolved in DRS into molten NGM medium to its required con-
centration of 2mg/ml. Liquid-based treatment was carried out by in-
cubating worms in ethosuximide dissolved in DRS/BSA droplets at the
speciﬁed concentrations and for the speciﬁed durations of time. PTZ
administration subsequent to either form of pharmacological exposure
was performed through a liquid-based approach (see above) in the
continued presence of the drug at the same concentration, by trans-
ferring nematodes to DRS/BSA droplets containing both PTZ and drug.
2.8. Scoring of seizure-like activity
The unc-49 model exhibits characteristic seizure-like head bobbing
movements and a paralysed posterior in response to PTZ (Williams
et al., 2004). We deﬁned a single head-bob as an extension and re-
traction of the anterior pharyngeal region of the worm, along the
anterior-posterior axis. These convulsions were stringently scored over
30-second durations in a qualitative and/or quantitative manner where
speciﬁed. Qualitative scoring assessed the overall presence or absence
of convulsions in a worm based on the threshold of three consecutive
head bobs, followed by subsequent determination of proportion of the
assayed population exhibiting seizure-like activity. The quantitative
approach scored the absolute number of head bobs over the same
duration. The diﬀerent scoring approaches complement each other, and
concurrent usage strengthens assessment of the phenotype. Phenotypes
were scored using a Zeiss Stemi 2000-C microscope (Carl Zeiss Limited,
Cambridge, USA) mounted on a Prior OptiScanIITM motorised micro-
scope stage (Prior Scientiﬁc Inc, Massachusetts, USA). Worm Tracker
(software version 2.0.3.1; http://www.mrc-lmb.cam.ac.uk/
wormtracker) was used to record videos of seizure-like activity,
which were then analysed manually to generate qualitative and quan-
titative data.
2.9. Thrashing assay
Motility was assessed by quantifying the rate of thrashing in DRS/
BSA as previously described (Johnson et al., 2009). A thrash was scored
as a head to tail sinusoidal movement, and thrashes were quantiﬁed
over a 1-min duration following an initial 10-min acclimatisation
period in DRS/BSA droplets.
2.10. Statistical analysis
All datasets were initially assessed using the Shapiro-Wilk test and
were found not to be normally distributed. Hence, the non-parametric
Mann-Whitney and Kruskal-Wallis tests were used to determine statis-
tical signiﬁcance. Analyses were performed on GraphPad Prism version
6 (GraphPad Software Inc.,California, USA). Data is presented as mean
values, with standard error of the mean (SEM) where appropriate.
3. Results
3.1. Development of a liquid-based PTZ assay
Previously, strains harbouring mutations in genes encoding a C.
elegans GABAA receptor (unc-49), glutamic acid decarboxylase (GAD;
unc-25), and calcium/calmodulin-dependent serine/threonine kinase II
(CaMKII; unc-43) were observed to exhibit either anterior-type “head
bobs” or full body contractions in response to the convulsant PTZ
(Williams et al., 2004) (Table 1). To ascertain if we could similarly
observe these phenotypes, we replicated the treatment procedure by
exposing all three strains to the convulsant agent on PTZ-containing
agar plates for 30min at concentrations ranging from 1 to 10mg/ml,
followed by scoring of the proportion of animals experiencing seizure-
like activity, as previously described (Williams et al., 2004). Consistent
with these published observations, PTZ-induced convulsions were
prominent in at least 20% of each sampled strain over most of the
concentrations tested (data not shown). Likewise, we conﬁrmed the
previous observation that, unlike these mutant strains, wild type N2
Table 1
Characteristics of PTZ-responsive C. elegans mutants used in this study. The human proteins listed are those exhibiting the highest amino acid homology to the
corresponding worm protein using BLASTP. The human genes listed are all of those that encode subunits of the functional human receptor/enzyme.
Worm gene Worm protein Function Human protein Human genes Human
epilepsy
mutations
Mutant worm
strain
PTZ-induced phenotype
unc-49 GABAA receptor GABAergic
inhibitory neuro-
transmission
GABAA receptor
β1/2/3 subunits
GABRA1-6
GABRB1-6
GABRD GABRE
GABRG1-3
GABRP
GABRQ
GABRR1-3
GABRA1
GABRB3
GABRD
GABRG2
unc-49 (e407)
III
Repetitive “head bob”
convulsions and paralysed
posterior
unc-25 Glutamic acid decarbox-ylase
(GAD)
GABA synthesis GAD 1 isoform 1 GAD1 GAD2 N/A unc-25 (e156)
III
unc-43 Calcium/calmodulin-
dependent serine/threonine
kinase II (CaMKII)
Phospho-regulation of
various physiological
processes
CamKII δ subunit
isoform δ11
CAMK2 A/B/
D/G
N/A unc-43 (n498
n1186) IV
Full body convulsions
And shrinking
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nematodes do not undergo convulsions in response to PTZ exposure.
Having successfully replicated the PTZ-induced seizure-like activity
reported previously (Williams et al., 2004), we then sought to improve
the eﬃciency and cost-eﬀectiveness of the procedure to facilitate drug
screening. Plate-based PTZ administration requires the preparation of
PTZ-containing agar plates, which is labour-intensive and incompatible
with modern high-throughput drug screens using compound libraries.
To overcome these issues, we adapted the treatment procedure from
plate-based to liquid-based by incubating the nematodes in small PTZ-
containing droplets. This method enables the direct and fresh
preparation of PTZ solutions in small volumes, hence not only permit-
ting the use of more stable formulations of PTZ, but also streamlining
the procedure by negating the need for additional preparation of drug-
containing agar plates.
An initial 5-point PTZ concentration-response analysis was per-
formed on all three mutant strains using the liquid droplet method,
which showed a concentration-dependent induction of convulsions that
peaked around 7mg/ml (Fig. 1A). Example movies of the head-bobbing
convulsions exhibited by unc-49 mutants and the full body convulsions
exhibited by unc-43mutants are shown in Supplementary videos S1 and
Fig. 1. Optimization of the liquid-based assay. (A) Worms were exposed to the indicated concentrations of PTZ in solution for 15min and then the proportion of
worms experiencing head-bobbing convulsions (unc-25, unc-49) or full body convulsions (unc-43) in 30 s was scored. unc-49 mutants exhibited the highest incidence
of seizure-like activity and were selected for further optimization. (B and C) unc-49 mutants were exposed to the indicated concentrations of PTZ for 15min and then
both the proportion of worms exhibiting head-bobbing convulsions (B) and the number of convulsions experienced per animal (C) was measured over 30 s. (D and E)
unc-49 mutants were exposed to 7mg/ml PTZ for the indicated times and then both the proportion of worms exhibiting head-bobbing convulsions (D) and the
number of convulsions experienced per animal (E) was measured over 30 s. Data shown were pooled from three independent experiments (n=27–30 worms in total
per concentration or time point).
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S2, respectively. Wild type N2 worms did not undergo convulsions at
any of the tested PTZ concentrations (data not shown). As unc-49 mu-
tants exhibited the highest incidence of seizure-like activity (Fig. 1A),
and as unc-49 is homologous to human GABAA receptor subunits that
are known to be mutated in various forms of epilepsy (Table 1), we
chose this strain for further optimisation. A more detailed, 7-point PTZ
concentration-response experiment was then performed, conﬁrming
that the incidence of convulsions was maximal at 5–7mg/ml PTZ
(Fig. 1B). Up to this point, seizure-like activity was solely scored as the
proportion of animals exhibiting convulsions, as previously described
(Williams et al., 2004), so we introduced a new approach to improve
stringency by concurrently quantifying the number of head bobs ex-
hibited by each animal over the 30-second scoring duration. In keeping
with the original scoring method, the frequency of PTZ-induced con-
vulsions was concentration-dependent, culminating and stabilising at
5–7mg/ml (Fig. 1C). We subsequently selected 7mg/ml based on the
rationale that seizure-like activity would be most robustly induced at
the highest convulsant concentration within this range. To determine
whether the 15-minute exposure to PTZ used in these initial experi-
ments was optimal, a time course experiment was performed. Both the
highest proportion of animals experiencing convulsions and the highest
number of convulsions per animal were observed after 15min of PTZ
exposure (Fig. 1D, E). After longer periods of PTZ exposure, the number
of convulsions per animal began to decline, due to progressive pa-
ralysis. Therefore, exposure of unc-49 mutants to 7mg/ml PTZ for
15min was established as the standard condition to be used for the
liquid-based assay
Next, we sought to establish if there is an age-dependent variability
in PTZ sensitivity in order to ascertain ﬁrstly if age-synchronized po-
pulations are required, and if so, the stage of the worm’s lifespan that
responds most robustly to PTZ. The optimised conditions described
above (Fig. 1) were determined using unsynchronized young adult
nematodes (approximately 1–3 days old), which were selected based on
the absence of visual morphological deterioration. Age-response ana-
lysis was therefore performed with age-synchronized populations mir-
roring these approximate ages. Although no signiﬁcant age-related
diﬀerences were detectable based on scoring the percentage of animals
exhibiting convulsions in response to PTZ (Fig. 2A); there was a sig-
niﬁcant decline in the number of convulsions exhibited per animal in 4-
day-old worms (Fig. 2B). This indicates that young adult nematodes of
mixed ages between days 1–3 may be utilised with negligible eﬀect on
PTZ-mediated induction of seizure-like activity, thereby eliminating the
need for laborious age-synchronization methods to be performed in
advance.
3.2. Optimization of the liquid-based assay for AED screening
Next, the ability of PTZ-induced seizure-like activity to be sup-
pressed by a known anticonvulsant was evaluated, in order to validate
the worm model as a potential AED screening platform. The AED
ethosuximide was chosen, as its anticonvulsive activity against PTZ-
induced seizures in rodent models is long established (Löscher, 2011).
As this was the ﬁrst attempt to demonstrate anticonvulsive activity of
ethosuximide in C. elegans, we selected 2mg/ml as an initial con-
centration, based on previous reports of lifespan extension in nema-
todes at ethosuximide concentrations between 1 and 4mg/ml (Chen
et al., 2015b; Choi et al., 2013; Collins et al., 2008; Evason et al., 2005;
Tauﬀenberger et al., 2013). These longevity eﬀects had been observed
with animals grown continuously on ethosuximide-containing agar
plates, so we initially adopted a similar long-term treatment procedure.
Unsynchronised, mixed stage mutant worms were cultured on NGM
agar plates containing 2mg/ml ethosuximide for two days prior to in-
cubation in ethosuximide- and PTZ-containing liquid droplets, to ensure
continuous exposure to the AED. To distinguish toxic from therapeutic
eﬀects of ethosuximide, we applied visual and phenotypic assessments
at the end of AED pre-treatment and/or PTZ exposure. Toxicity was
determined by visual observations of abnormal stiﬀ movement or im-
mobility, and a weak response to touch. Conversely, a therapeutic eﬀect
was deﬁned by a reduction in or abolition of convulsions in the pre-
sence of movement and a normal response to touch. The absence of
convulsions in immobile worms was only considered therapeutic if a
robust response to touch was observed, indicative of non-toxicity. In
line with these criteria, ethosuximide exerted a signiﬁcant therapeutic
reduction in the incidence of PTZ-induced seizure-like activity in both
unc-25 and unc-49 mutants, but had no discernible eﬀect on unc-43
worms (Fig. 3A).
Drowsiness and sedation are reported adverse eﬀects associated
with ethosuximide treatment in patients (Patsalos, 2013). Therefore, we
investigated if the anticonvulsive eﬀects of the drug observed in unc-25
and unc-49 strains may be attributed to mutant-speciﬁc impairment of
movement that does not occur in unc-43 worms. Locomotion was
therefore assessed via the frequency of thrashes in a liquid medium in
order to test this possibility. Example movies showing the thrashing
activity of N2 and unc-49 strains are shown in Supplementary video S3
Fig. 2. Responses to PTZ are not age-dependent in younger worms.
unc-49 mutants were age-synchronised by bleaching and grown to the indicated ages before being exposed to 7mg/ml PTZ in solution for 15min. At this point, the
proportion of worms exhibiting head-bobbing convulsions (A) and the number of convulsions experienced per animal (B) were measured over 30 s. No age-associated
diﬀerence in PTZ responsiveness was seen when the proportions of animals exhibiting convulsions were scored (A); but the mean number of convulsions per worm
(B) was signiﬁcantly reduced in 4-day-old adults as compared to younger ages of days 1 and 2. Data shown were pooled from three independent experiments
(n=27–30 worms in total per adult age point). Statistical analysis was performed with the Kruskal-Wallis test with Dunn's correction for multiple comparisons; *,
p < 0.05.
S.Q. Wong et al. Journal of Neuroscience Methods 309 (2018) 132–142
136
and S4, respectively. Ethosuximide treatment had no signiﬁcant eﬀect
on wild type N2 worms but reduced the thrashing rates of all three unc
mutant strains by approximately 50% (Fig. 3B). However, as ethosux-
imide decreased unc-43 motility despite having no discernible antic-
onvulsive activity in this mutant, it is unlikely that the protection from
seizure-like activity in unc-25 and unc-49 mutants is simply due to
impaired movement.
Ethosuximide administration via a two-day agar plate-based ex-
posure (Fig. 3) is time-consuming and incompatible with modern
compound library screening approaches. In order to develop a faster,
liquid-based method, we performed a time-course investigation by pre-
incubating unc-49 mutants in ethosuximide-containing droplets for up
to 3 h prior to PTZ exposure. An initial concentration of 2mg/ml
ethosuximide was chosen, as this was eﬀective in the agar plate-based
experiments (Fig. 3). However, given that the optimal anticonvulsive
concentration of ethosuximide when applied in solution was yet to be
determined, variability was anticipated in responses to the drug at
various time-points. Despite this, a time-dependent reduction in both
convulsion incidence and absolute convulsion number was observed
after 30min of drug treatment, although seizure-like activity was not
completely abolished even after the longest treatment duration of 3 h
(Fig. 4A and B). As the frequencies of head bobbing convulsions ap-
peared to stabilise after an hour of drug treatment (Fig. 4B), we selected
an intermediate duration of 2 h as the preferred drug exposure time.
This 2-hour pre-treatment protocol was then used to determine the
optimal anticonvulsant concentration of ethosuximide, demonstrating a
concentration-dependent reduction in convulsions that reached com-
plete abolition at 4mg/ml (Fig. 4C and D). Importantly, this convul-
sion-free state of unc-49 worms was not due to ethosuximide-induced
paralysis, as the movement of the worms in PTZ solution actually be-
came more coordinated after ethosuximide treatment (Supplementary
video S5).
Ethosuximide is water-soluble and was therefore solubilised in an
aqueous medium to optimise these drug screening conditions. However,
chemicals from compound libraries are mostly maintained and screened
as solutions solubilised with dimethyl sulfoxide (DMSO) as a vehicle,
necessitating the unc-49 platform to be further adapted for a broader
screening applicability. Given that DMSO can have toxic eﬀects on C.
elegans (Boyd et al., 2010), it was important to determine the tolerable
threshold of DMSO that does not cause observable toxicity according to
the aforementioned criteria, and does not aﬀect responses to PTZ.
Therefore, screening conditions were mimicked by exposing unc-49
mutants to varying concentrations of DMSO throughout the intended 2-
hour drug treatment and 15-minute PTZ exposure windows. Convul-
sions induced by PTZ were unaﬀected by up to 1% DMSO, but further
increases in DMSO resulted in a concentration-dependent reduction in
response to the convulsant (Fig. 5). This decreased responsiveness to
PTZ was likely due to DMSO toxicity, as these higher concentrations of
DMSO resulted in severe movement defects and visible toxicity-asso-
ciated behavioural abnormalities as deﬁned previously. Furthermore,
these phenotypic aberrations were clearly distinguishable from the
therapeutic-associated more coordinated movement observed in etho-
suximide-treated worms. Since sensitivity to PTZ was evidently im-
paired with ≥ 2% DMSO, future AED screens using DMSO-solubilized
compounds should ideally be performed using no more than 1% DMSO.
3.3. Chemical genetic testing of AED mechanism of action
One major advantage of using a C. elegans model is the ability to use
powerful genetic approaches to examine potential mechanisms of drug
action in vivo. This possibility was therefore assessed with the new
assay. Ethosuximide has been prescribed for 60 years and is still used as
a ﬁrst-line treatment against absence epilepsy in children, but its mo-
lecular mechanism of action remains unclear. Although ethosuximide
has been suggested to exert its antiepileptic eﬀect by inhibiting T-type
voltage-gated calcium channels (Coulter et al., 1989a,b 1990; Gomora
et al., 2001; Lacinova et al., 2000), this is controversial and several
alternative targets have been suggested (Crunelli and Leresche, 2002;
Fohlmeister et al., 1984). To investigate if these channels constitute the
AED’s molecular target against PTZ-induced convulsions in C. elegans,
we deleted the worm T-type calcium channel-encoding cca-1 ortho-
logue in unc-49 mutants by genetically crossing them with a loss-of-
function cca-1 mutant to generate double mutant unc-49;cca-1 animals.
Three independently-derived lines were genetically veriﬁed for both
mutations (Supplementary Figure S1), and assayed to validate the re-
producibility of responses to drug treatment and PTZ exposure. The
single cca-1 mutant did not exhibit seizures in response to PTZ, similar
to wild type strains (Fig. 6; Supplementary video S6). Loss of functional
CCA-1 had no signiﬁcant eﬀect on the ability of PTZ to evoke convul-
sions in double unc-49;cca-1 mutants (Supplementary video S7). The
anticonvulsant activity of 4mg/ml ethosuximide was unaﬀected by
mutation of cca-1, as both the proportion of convulsing worms (Fig. 6A)
Fig. 3. Ethosuximide reduces seizure-like activity in GABAergic mutant strains.
(A) Worms were cultured on agar plates containing ethosuximide or vehicle control for 2 days before incubation in a 7mg/ml PTZ solution for 15min. The
proportion of worms experiencing head-bobbing convulsions (unc-25, unc-49) or full body convulsions (unc-43) in 30 s was then scored. The incidence of PTZ-induced
seizure-like activity was signiﬁcantly reduced by ethosuximide treatment in unc-25 and unc-49mutants, but not unc-43mutants. Wild type N2 worms did not undergo
convulsions in response to PTZ. (B) Worms were cultured on agar plates containing ethosuximide or vehicle control for 2 days before incubation in Dent’s Ringer
solution for 10min. The number of thrashing movements made by each worm in 60 s was then scored. Ethosuximide signiﬁcantly reduced the thrashing frequency of
all mutant strains, but had no eﬀect on wild type N2 worms. Data shown were pooled from three independent experiments (n = 30 worms in total per strain per
condition), with statistical comparisons made via the Mann-Whitney test; *, p < 0.05.
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Fig. 4. Optimization of liquid-based AED screening conditions using ethosuximide in unc-49 mutants.
(A and B) unc-49 mutants were pre-incubated in a solution containing 2mg/ml ethosuximide for the indicated times; or (C and D) were pre-incubated for 2 h in the
indicated concentrations of ethosuximide. The worms were then exposed to 7mg/ml PTZ for 15min and the proportion of worms exhibiting head-bobbing con-
vulsions (A and C) and the number of convulsions experienced per animal (B and D) were measured over 30 s. Complete abolition of convulsions was achieved with a
2-hour incubation at 4mg/ml ethosuximide. Data shown were pooled from three independent experiments (n= 10–15 worms in total per drug treatment time-point
or concentration).
Fig. 5. Identiﬁcation of non-toxic DMSO levels for drug screens in unc-49 mutants. Worms were exposed to the indicated concentrations of DMSO throughout a 2-
hour pre-incubation period and a 15-minute PTZ exposure period. (A) The proportion of worms exhibiting convulsions and (B) the mean number of convulsions per
animal were then scored over 30 s. PTZ responsiveness was unaﬀected up to 1% DMSO, but higher DMSO concentrations resulted in toxicity that reduced sensitivity
to PTZ. Data shown were pooled from three independent experiments (n= 10–15 worms in total per DMSO concentration).
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and the mean number of head bobs exhibited per animal (Fig. 6B) were
comparable in double unc-49;cca-1 mutants and single unc-49 mutants
containing wild type CCA-1. Importantly, the same concentration of the
chemically similar but biologically inert molecule succinimide con-
ferred no protection from PTZ-induced convulsions in single unc-49
mutants (Fig. 6) or double unc-49;cca-1 mutants (Supplementary video
S7), demonstrating that the anticonvulsant activity of ethosuximide was
speciﬁc to the drug and not due to non-speciﬁc eﬀects of the treatment
conditions. We therefore conclude that ethosuximide does not prevent
PTZ-induced convulsions in unc-49 mutants by inhibiting T-type cal-
cium channels.
4. Discussion
Building on previously-reported observations of PTZ-induced sei-
zure-like activity in GABAergic and CaMKII C. elegans mutants
(Williams et al., 2004), we have generated a reﬁned platform using unc-
49 GABAA receptor mutants. Using our streamlined approach, char-
acteristic head-bobbing convulsions were initiated through liquid-based
PTZ exposure, resulting in a two-fold reduction in the exposure time
required for optimal induction of seizure-like activity compared to the
agar plate-based method used in the original study. Our liquid-based
method of administering both PTZ and AED through droplet incubation
oﬀers two further advantages. Firstly, throughput is increased and cost
is reduced, since tedious and more expensive PTZ and drug plate pre-
parations are not required. Secondly, our reﬁned technique is better
suited to the use of compound libraries. Since the latter are typically
prepared as stock solutions in DMSO in microtitre plates, diluted so-
lutions for screening can be easily and directly prepared in micro-titre
formats, especially with the use of robotic platforms (Buckingham et al.,
2014). Furthermore, we have demonstrated that PTZ responsiveness is
unaﬀected by DMSO concentrations up to 1%, thereby facilitating
screening of DMSO-solubilised compound libraries. Additional stream-
lining of the screening process could potentially be achieved using
robotic systems for automated culturing and handling of nematodes,
which are also adaptable for micro-titre plate conﬁgurations
(Bazopoulou et al., 2017; Boyd et al., 2010; Xian et al., 2013). Although
we have demonstrated that precise age synchronization is not essential
for our platform, since 1- to 3-day-old adult worms respond similarly to
PTZ, current technologies enabling the sorting of C. elegans by age and/
or size could potentially be used to further enhance the assay by fa-
cilitating automated selection of young adult nematodes (Boyd et al.,
2010; Pulak, 2006; Rezai et al., 2012).
Despite these advantages, one caveat of our system is the use of
visual scoring of the characteristic head-bobbing convulsions. Manual
scoring of convulsions is inherently liable to subjectivity, and so the
implementation of an automated scoring method would standardize
scoring parameters and greatly improve the throughput of our
screening platform. Given that such automated scoring technologies
have already been developed for other phenotypes in C. elegans
(Buckingham et al., 2014), this is likely achievable for the head-bob-
bing phenotype with the implementation of algorithms and parameters
to strictly diﬀerentiate between seizure-like activity and other beha-
viours. A further potential limitation of our system is the use of the unc-
49 GABAA receptor mutant background, which may produce false ne-
gatives for AEDs that directly or indirectly target GABAA receptors. This
issue is mitigated to some extent by the fact that unc-49 is only one of
seven GABAA receptor-encoding genes in the worm genome (others
being gab-1, lgc-35, lgc-36, lgc-37, lgc-38 and exp-1), so GABAA-receptor-
binding drugs should still be able to exert eﬀects (Gendrel et al., 2016).
Finally, some classes of AEDs may have no activity in our assay because
their target proteins are not expressed in worms. For example, the C.
elegans genome does not encode voltage-gated sodium channels
(Bargmann, 1998), which are the most common molecular target of
currently prescribed AEDs. However, if the goal is to discover new AEDs
with novel molecular targets, perhaps using an animal model that lacks
one of the best established drug targets could be argued to be an ad-
vantage.
Fig. 6. Ethosuximide does not mediate anticonvulsant eﬀects through the T-type calcium channel, CCA-1. Three unc-49 lines harbouring a loss-of-function mutation
in the T-type voltage-gated calcium channel-encoding cca-1 gene (unc-49;cca-1) were generated. These and the parent unc-49 single mutant strain were pre-incubated
for 2 h in a solution containing either 4mg/ml ethosuximide or 4mg/ml succinimide, before exposure to PTZ for 15min. The loss of these channels did not aﬀect
protection from seizure-like activity by ethosuximide, as the drug (A) prevented overall convulsions and (B) signiﬁcantly reduced the convulsion rates in all lines
when compared to unc-49 worms treated with the inert succinimide control (p < 0.05). Furthermore, anticonvulsant activity in all lines were comparable to cca-1-
intact ethosuximide-treated unc-49 controls (p > 0.05). Data shown were pooled from three independent experiments, with convulsion rates compared via the
Kruskal-Wallis test with Dunn’s multiple comparison correction (n=13–15 worms in total per strain per condition); *, p < 0.05.
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In order for a worm assay to be potentially useful for novel AED
screening, clinically approved AEDs must ﬁrst be shown to protect
against convulsions as a proof of principle. Here, we validated the unc-
49 platform by replicating the long-established anticonvulsant eﬀect of
ethosuximide seen in traditional rodent PTZ seizure models (Chen et al.,
1963; Löscher, 2011). Pre-incubation for 2 h in a bathing solution of
4mg/ml ethosuximide greatly reduced seizure-like activity and also
improved the uncoordinated movement of PTZ-treated unc-49 mutant
worms. Based on previous studies of ethosuximide accumulation in C.
elegans (Evason et al., 2005) and the linear relationship between
ethosuximide dosage and serum/CSF concentration in humans
(Patsalos, 2005), we estimate that the internal concentration of etho-
suximide in worms bathed in a 4mg/ml solution is approximately 440
μM. This value is within the known human therapeutic serum con-
centration range of 280–700 μM (Goren and Onat, 2007), further sup-
porting the pharmacological validity of our worm assay. Chemical
screens have previously been performed in both heat- and electroshock-
induced C. elegans models of seizure-like activity (Pandey et al., 2010;
Risley et al., 2016). However, the anticonvulsive eﬀects of known AEDs
against heat-induced convulsions was not demonstrated. Although
several established AEDs were assessed in the electroshock model,
protective eﬀects were evaluated based on improvement of the recovery
time from convulsions after removal of the electric stimulus, as opposed
to inhibition of convulsions per se. Despite these limitations, both
models have potential utility for compound library screening. Our
system, using PTZ exposure in unc-49 mutants, oﬀers a complementary
platform that is already validated using a currently prescribed AED
based on a direct readout of convulsion reduction. Applications of our
model include unbiased compound screens to ﬁnd novel anticonvulsant
molecules as well as chemical modiﬁcation of existing AEDs to facilitate
drug repurposing. Indeed, we have recently used the unc-49 assay to
rapidly pre-screen ethosuximide-based compounds for bioactivity be-
fore subsequent testing for increased neuroprotective potency (Wong
et al., 2018). In view of the large number of rodents used as acute
seizure models in AED discovery, C. elegans assays could be a more
economical and ethical alternative.
The ease of genetic manipulation in C. elegans and the availability of
mutants covering most of the genome facilitates the rapid creation of
genetic epilepsy models. Indeed, the unc-49 mutant characterised
herein (Bamber et al., 1999) and the aforementioned acr-2 mutant
(Jospin et al., 2009) contain mutations in C. elegans homologues of
human GABAA and nicotinic acetylcholine receptor genes, respectively,
which have been linked to various forms of epilepsies (Audenaert et al.,
2006; Baulac et al., 2001; Chen et al., 2009; Cossette et al., 2002; Epi
et al., 2013; Fusco et al., 2000; Gambardella et al., 2003; Harkin et al.,
2002; Hirose et al., 1999; Kananura et al., 2002; Lachance‐Touchette
et al., 2011; Leniger et al., 2003; Lerche et al., 2013; Marini et al., 2003;
Phillips et al., 2001; Rozycka et al., 2003; Sáenz et al., 1999; Steinlein
et al., 1997, 1995; Sun et al., 2008; Wallace et al., 2001; Wang et al.,
2017). These links to genetic epilepsies therefore provide a basis for the
clinical relevance of both acr-2 and unc-49 platforms. Furthermore,
chemical genetic approaches can be performed rapidly in C. elegans to
shed light on the mechanisms of action of currently prescribed AEDs,
which are often poorly understood. Indeed, ethosuximide has been
variously suggested to inhibit T-type calcium channels (Coulter et al.,
1989a, 1990, 1989b; Gomora et al., 2001; Lacinova et al., 2000), vol-
tage-gated sodium channels and potassium channels (Fohlmeister et al.,
1984); to activate forkhead box O (FOXO) transcription factors (Chen
et al., 2015b); and to modulate the phosphoinositide 3-kinase/AKT/
Wnt/β-catenin signalling pathway (Tiwari et al., 2015). Our proof-of-
concept chemical genetics investigation has clearly demonstrated that
ethosuximide’s anticonvulsant eﬀect is not mediated by the C. elegans T-
type calcium channel CCA-1. The inability of ethosuximide to rescue
the full-body convulsions in unc-43 null mutants could potentially
suggest that UNC-43 (CAMKII) or a CAMKII-phosphorylated substrate
protein(s) may be the molecular target of ethosuximide. However, there
are no published data linking ethosuximide to CAMKII, so evidence for
this proposition is lacking. Nevertheless, although we have not yet
identiﬁed ethosuximide’s molecular target, the ease of conducting
genome-wide genetic screens in C. elegans suggests that this could be
feasibly achieved using our assay.
5. Conclusions
In conclusion, we have developed a streamlined assay in C. elegans
suitable for early-stage AED screening. We envisage that this could be
used in future as the ﬁrst pass in a pipeline for drug discovery, with
promising compounds being prioritised for validation in conventional
rodent models, thus reducing the ethical and ﬁnancial costs of AED
screening. In addition, the C. elegans system enables rapid identiﬁcation
of the mechanisms of action of such validated novel AEDs via chemical
genetics.
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